The Viral Hemorrhagic Fever Immunotherapeutic Consortium, or VIC, was established in 2014 to develop life-saving antibody therapeutics against some of the world’s deadliest viruses. The VIC represents a field-wide collaboration in which leading laboratories around the world have united to understand what fetaures lead to antibody-mediated protection againt these viruses and how we can more rapidly discover ideal treatments. This collaborative effort allows each laboratory to contribute their strengths in analytical techniques towards the identification, characterization, and validation of antibodies against the filoviridae and arenaviridae families. From isolating novel antibodies and testing them in vivo, to the structural analysis of the molecular mechanisms of neutralization, VIC scientists contribute unique insights towards the overall characterization of a broad pool of antibodies. The consortium is funded through a National Institute of Health National Institute of Allergy and Infectious Diseases Centers for Excellence in Translational Research program grant.

Recent News

Another facet of Antibody-Mediated Protection: Fc-Driven Immune Effector Function of Antibodies Against Ebola Virus Glycoprotein

August 9, 2018

Antibodies targeting the Ebola virus glycoprotein that lack neutralization activity can nonetheless offer protection by promoting activation of natural killer (NK) cells and monocyte phagocytosis.  (from Gunn et al. Cell Host Microbe https://doi.org/10.1016/j.chom.2018.07.009) In a companion publication to the Saphire et al.Cell manuscript published online in Cell Host Microbe on August 7, 2018 Gunn et … Continued

VIC Study Reveals the Importance of a Two-Pronged Attack to Prevent Ebola Virus Infection

VIC researchers analyzed features for each of 171 monoclonal antibodies in the VIC panel to define correlations between antibody characteristics and ability to offer protection (Graphical abstract from Saphire et al. doi: 10.1016/j.cell.2018.07.033)   In their paper published online on August 9, 2018 in Cell the VIC describes findings from a multi-year study conducted on … Continued

Fort Detrick Researchers Seek Key to Ebola Virus

September 23, 2016

Dr. John Dye, a VIC collaborator, investigates the mechanism behind the ability to survive Ebola virus infection in Uganda.  Travelling to Uganda and collecting samples directly from Ebola survivors allows him to analyze the different physiological mechanisms that have enabled these individuals to survive while many others have perished.  This research contributes to our understanding of … Continued